Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
V.AFM: Record Fy2024 & Q4 ‘24 Tin Production Fy2025 Production Guidance Exploration Success (click to learn more) Noble Acquires Property with Significant Uranium, Rare Earth, Phosphorus & Silver Minerlaization (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GILD)

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

Business Wire 8 days ago

Gilead Sciences to Present at Upcoming Investor Conference

Business Wire December 20, 2024

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Business Wire December 17, 2024

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

Business Wire December 17, 2024

Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

Business Wire December 13, 2024

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

Business Wire December 12, 2024

Kite's Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024

Business Wire December 9, 2024

Longest Follow-Up Data Reported for Kite's Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

Business Wire December 9, 2024

Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH

Business Wire December 8, 2024
View More News ››

Opinion & Analysis (NDAQ:GILD)

Gilead, Teva, XPhyto - Global marketing potential

Stockhouse Editorial June 16, 2020

BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

Stockhouse Editorial April 24, 2020

BioNTech, Gilead, Memphasys - modern science and COVID and IVF

Stockhouse Editorial March 19, 2020

Galapagos Agrees to $3.95 Billion, 10-Year Licensing Deal Plus $1.1 Billion Investment from Gilead

Streetwise Reports July 16, 2019

With acquisition of Kite Pharma, Gilead becomes a 'major player' in CAR-T arena

The Life Sciences Report August 30, 2017

HIV vaccine clinical study results in high immune response rates in healthy subjects

The Life Sciences Report June 2, 2017
View More Opinion ››

Bullboard Posts (NDAQ:GILD)

Gilead and the Elton John AIDS Foundation Announce Additiona

Just In: $GILD Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the...
whytestocks - July 22, 2024

Biotechs Race to Develop New Treatments as Global Pancreatic

NEWS: $GILD Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 20332024...
whytestocks - June 20, 2024

Outperform Recommendation Issued On GILD By Evercore ISI

BREAKING NEWS: $GILD Outperform Recommendation Issued On GILD By Evercore ISI2024-06-14 15:15:06 ET Evercore ISI analyst issues...
whytestocks - June 14, 2024

Sector Perform Recommendation Issued On GILD By UBS

News; $GILD Sector Perform Recommendation Issued On GILD By UBS2024-06-14 15:15:06 ET UBS analyst issues SECTOR PERFORM recommendation...
whytestocks - June 14, 2024

Why Gilead Sciences Stock Got Mashed on Monday

JUST IN: $GILD Why Gilead Sciences Stock Got Mashed on Monday2024-01-22 18:08:02 ET Pharmaceutical sector mainstay Gilead Sciences...
whytestocks - January 22, 2024

Gilead Provides Update on Phase 3 EVOKE-01 Study

JUST IN: $GILD Gilead Provides Update on Phase 3 EVOKE-01 StudyGilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3...
whytestocks - January 22, 2024
View more Bullboard ››

Tribe Property Technologies Inc.

Tribe Property Technologies Inc.

Tribe Property Technologies Inc. is a property technology company. The Company offers technology-enabled property management ...
View More »